Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

835
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
835
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

169
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
169
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

222
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
222

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repairing critical-sized calvarial defects with BMSCs modified by a constitutively active form of hypoxia-inducible factor-1α and a phosphate cement scaffold.

Biomaterials·2011
Same author

Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2011
Same author

Fast and efficient fully 3D PET image reconstruction using sparse system matrix factorization with GPU acceleration.

Physics in medicine and biology·2011
Same author

Profiling of the tetraspanin CD151 web and conspiracy of CD151/integrin β1 complex in the progression of hepatocellular carcinoma.

PloS one·2011
Same author

Detailed assessment of isotope ratio infrared spectroscopy and isotope ratio mass spectrometry for the stable isotope analysis of plant and soil waters.

Rapid communications in mass spectrometry : RCM·2011
Same author

[Enhancement of osteoblastic differentiation of bone marrow mesenchymal stem cells in rats by sinusoidal electromagnetic fields].

Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi·2011

Related Experiment Video

Updated: Jun 27, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

331

RNA modifications in pulmonary diseases.

Weiwei Qian1,2, Lvying Yang3, Tianlong Li4

  • 1Emergency Department of Emergency Medicine Laboratory of Emergency Medicine, West China Hospital, And Disaster Medical, Sichuan University Chengdu Sichuan China.

Medcomm
|May 6, 2024
PubMed
Summary
This summary is machine-generated.

RNA epigenetic modifications are key in pulmonary diseases (PD). This review details critical modifications like N6-methylation and pseudouridine, highlighting their potential as biomarkers and therapeutic targets for early diagnosis and treatment.

Keywords:
RNA modification databaseRNA modificationsfunctions of RNA modificationspulmonary diseases

More Related Videos

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

10.6K
Protein Transfection of Mouse Lung
04:21

Protein Transfection of Mouse Lung

Published on: May 15, 2013

9.4K

Related Experiment Videos

Last Updated: Jun 27, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

331
Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

10.6K
Protein Transfection of Mouse Lung
04:21

Protein Transfection of Mouse Lung

Published on: May 15, 2013

9.4K

Area of Science:

  • Molecular Biology
  • Pulmonary Medicine
  • Epigenetics

Background:

  • Pulmonary diseases (PD) represent a significant global health burden, encompassing conditions such as chronic obstructive pulmonary disease, pulmonary fibrosis, asthma, infections, and lung cancer.
  • Emerging evidence highlights the pivotal role of RNA epigenetic modifications in the pathogenesis of various pulmonary diseases.
  • These modifications influence cellular processes and gene expression, impacting disease progression.

Purpose of the Study:

  • To review and summarize critical RNA epigenetic modifications implicated in the development and progression of pulmonary diseases.
  • To explore the regulatory mechanisms governing these modifications.
  • To underscore the potential of RNA modifications as biomarkers and therapeutic targets for pulmonary diseases.

Main Methods:

  • Literature review and synthesis of existing research on RNA epigenetic modifications in pulmonary disease.
  • Detailed summary of key RNA modifications including N6-methylation of adenosine, N1-methylation of adenosine, 5-methylcytosine, pseudouridine, 7-methylguanosine, and adenosine to inosine editing.
  • Discussion of the regulatory pathways involved in these epigenetic changes.

Main Results:

  • Several RNA epigenetic modifications, including N6-methylation of adenosine, N1-methylation of adenosine, 5-methylcytosine, pseudouridine, 7-methylguanosine, and adenosine to inosine editing, are critically involved in pulmonary disease pathogenesis.
  • These modifications dynamically regulate gene expression and cellular functions relevant to lung injury and disease.
  • Understanding these mechanisms provides insights into disease pathology.

Conclusions:

  • RNA epigenetic modifications are crucial players in pulmonary disease development and progression.
  • These modifications offer promising avenues for the identification of novel diagnostic biomarkers and innovative therapeutic strategies for pulmonary diseases.
  • Further research into RNA epigenetics could lead to advancements in early diagnosis and treatment of lung conditions.